Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/09/2019 10/10/2019 10/11/2019 10/14/2019 10/15/2019 Date
61.98(c) 63.26(c) 63.99(c) 64.51(c) 65.3(c) Last
3 655 779 5 847 015 5 650 620 4 558 996 5 730 401 Volume
+0.47% +2.07% +1.15% +0.81% +1.22% Change
More quotes
Financials (USD)
Sales 2019 22 345 M
EBIT 2019 11 662 M
Net income 2019 4 272 M
Finance 2019 649 M
Yield 2019 3,86%
Sales 2020 22 672 M
EBIT 2020 11 463 M
Net income 2020 7 100 M
Finance 2020 544 M
Yield 2020 4,19%
P/E ratio 2019 18,5x
P/E ratio 2020 11,4x
EV / Sales2019 3,67x
EV / Sales2020 3,62x
Capitalization 82 700 M
More Financials
Company
Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (98.5% of net sales) and other (1.5%; primarily... 
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
10/15New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio
DJ
10/15GILEAD SCIENCES INC : Change in Directors or Principal Officers, Financial State..
AQ
10/15GILEAD SCIENCES : Names Andrew Dickinson Chief Financial Officer
DJ
10/15GILEAD SCIENCES : Appoints Andrew Dickinson as Chief Financial Officer
BU
10/10GILEAD SCIENCES : Galapagos See Efficacy in Advanced Rheumatoid Arthritis Study
DJ
10/10GILEAD SCIENCES : to Release Third Quarter 2019 Financial Results on Thursday, O..
BU
10/08GILEAD SCIENCES : Submits New Drug Application for Filgotinib for the Treatment ..
BU
10/07Gilead Sciences Names Merdad Parsey Chief Medical Officer
DJ
10/07GILEAD SCIENCES : Appoints Merdad Parsey, MD, PhD as Chief Medical Officer
BU
10/07GILEAD SCIENCES : Presents New Data From the Company's HIV Clinical Development ..
AQ
10/04GILEAD SCIENCES : U.S. Food and Drug Administration Approves Descovy for HIV Pre..
AQ
10/04GILEAD SCIENCES INC. : - U.S. Food and Drug Administration Approves Descovy for ..
AQ
10/04GILEAD SCIENCES : Presents New Data From the Company's HIV Clinical Development ..
BU
10/03GILEAD SCIENCES : Says FDA Approves Descovy for HIV Pre-Exposure Prophylaxis
DJ
10/03GILEAD SCIENCES : U.S. Food and Drug Administration Approves Descovy® for HIV Pr..
BU
More news
News in other languages on GILEAD SCIENCES
10/10Wall Street : Trump ravive espoir d'1 accord, Apple au zénith
09/12GILEAD SCIENCES : Ex-dividend day for
09/03AKTIEN EUROPA : Verluste - Brexit-Sorgen wieder im Fokus
08/26GALAPAGOS : accord avec Gilead finalisé
08/16GILEAD : avancée pour filgotinib en Europe
More news
Analyst Recommendations on GILEAD SCIENCES
More recommendations
Sector news : Bio Therapeutic Drugs
10/10GILEAD SCIENCES : Galapagos See Efficacy in Advanced Rheumatoid Arthritis Study
DJ
10/10Snakes and ladders - SoftBank Vision Fund's climbing, sliding valuations
RE
10/09BAYER : to Advance Ionis Pharma's Clotting Medicine
DJ
10/08Thermo Fisher Scientific Sees Largest Percent Decrease Since October 2011 -- ..
DJ
10/08Qiagen CEO quits amid genetic sequencing U-turn, shares tumble
RE
More sector news : Bio Therapeutic Drugs
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 80,29  $
Last Close Price 65,30  $
Spread / Highest target 45,5%
Spread / Average Target 23,0%
Spread / Lowest Target -8,12%
EPS Revisions
Managers
NameTitle
Daniel O'Day Chairman & Chief Executive Officer
Robin L. Washington CFO, Chief Accounting Officer & Executive VP
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
John Francis Cogan Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES4.40%82 700
VERTEX PHARMACEUTICALS4.76%44 619
REGENERON PHARMACEUTICALS-18.66%33 422
WUXI APPTEC CO., LTD.65.14%20 257
GENMAB25.01%12 912
NEUROCRINE BIOSCIENCES, INC.30.92%8 326